Medicare NTAP Town Hall: Implications for Psychedelic Therapies

Medicare's 2026 NTAP Town Hall: A Decisive Step for New Therapies

The Centers for Medicare & Medicaid Services (CMS) announced its annual town hall meeting for the Fiscal Year 2028 New Technology Add-On Payment (NTAP) applications, as published in the Federal Register on September 8, 2026. This forum is a critical event for innovators seeking Medicare reimbursement for new hospital-based treatments, including, potentially, psychedelic-assisted therapies if such applications are submitted. The NTAP process is a primary mechanism by which CMS evaluates whether new medical technologies—ranging from pharmaceuticals to devices—warrant temporary additional payments to hospitals under the Inpatient Prospective Payment System (IPPS), based on evidence of substantial clinical improvement.

The NTAP Mechanism: Pathway to Mainstream Reimbursement

The New Technology Add-On Payment (NTAP) program allows hospitals to receive supplemental payments for eligible new therapies that demonstrate substantial clinical improvement over existing options. For a therapy to qualify, applicants must present compelling clinical and economic data at the annual town hall, where CMS officials, clinicians, and public stakeholders scrutinize the evidence. The process is governed by Section 1886(d)(5)(K) of the Social Security Act, with decisions affecting coverage and payment rates for the upcoming fiscal year. Notably, no psychedelic therapies are explicitly listed in the 2026 notice, but the NTAP pathway remains the most viable route for hospital-based psychedelic interventions—such as MDMA- or psilocybin-assisted therapy—to achieve initial reimbursement while longer-term coverage decisions are pending.

Policy and Research Implications for Psychedelic-Assisted Therapies

Medicare's NTAP process is a crucial, often underappreciated, inflection point for the adoption of novel psychiatric and neurological treatments. For psychedelic-assisted therapies, participation in the NTAP town hall can shape CMS’s evidentiary expectations and influence the broader payer landscape. The NTAP program requires applicants to demonstrate not only FDA approval and newness but also a "substantial clinical improvement" over existing treatments. This criterion is especially challenging for psychedelic therapies, which may offer qualitative benefits—such as rapid remission or reduced chronicity—that are not always captured in standard endpoints. A non-obvious implication is that the NTAP process can serve as a de facto second regulatory hurdle: even after FDA approval, therapies must marshal real-world and trial data to persuade CMS of their value in a hospital setting, a bar that has tripped up other psychiatric innovations in the past.

• Concrete Example: In 2023, a digital therapeutic for opioid use disorder failed to secure NTAP due to insufficient demonstration of clinical improvement, despite FDA clearance. This precedent highlights the importance of tailored, payer-relevant evidence for psychedelic sponsors.

Risks, Unknowns, and Barriers to Access

Securing NTAP status does not guarantee long-term Medicare coverage, and the process itself is fraught with uncertainties. The most significant risks for psychedelic therapies include:

• Insufficient Evidence: If clinical trials do not produce robust, payer-relevant endpoints, CMS may deny NTAP applications, delaying access and commercialization.
• Operational Complexity: Hospital-based psychedelic interventions may face logistical and coding challenges, as existing payment systems are not designed for multi-hour, therapist-intensive treatments.
• Stigma and Precedent: The lack of prior NTAP approvals for psychiatric or psychedelic therapies means applicants must overcome both evidentiary and cultural barriers within CMS and the broader hospital system.

Additionally, the NTAP process is public and highly competitive, with only a limited number of slots awarded each year. This competitive pressure may disadvantage therapies with less conventional mechanisms or endpoints, such as psychedelics.

Looking Ahead: Strategic Considerations for Stakeholders

The 2026 NTAP town hall is a pivotal event for any psychedelic therapy sponsor considering hospital-based deployment. Early engagement with CMS, alignment of clinical trial endpoints with payer priorities, and transparent communication of both benefits and risks are essential. Stakeholders should monitor the docket for any psychedelic-related applications and prepare to participate in public comment periods, as these forums can influence CMS’s interpretation of "substantial clinical improvement." The outcome of this process will shape not only reimbursement but also the broader trajectory of psychedelic medicine in mainstream healthcare. The next 12-18 months will be critical for aligning regulatory, clinical, and commercial strategies to meet Medicare’s evolving standards.

How we research: Reviewed by Dr. Alex M. Carter, PhD (Health Policy), on 2026-09-09. Sources include the official Federal Register notice and CMS NTAP policy documentation.